RApid Fluid Volume EXpansion in Patients in Shock After the Initial Phase of Resuscitation. (RAVEXO)
Shock, Hypovolemia
About this trial
This is an interventional treatment trial for Shock focused on measuring Fluid Therapy, Plasma Substitutes, Fluid Balance
Eligibility Criteria
Pre-eligibility criteria:
- Patients presenting on Intensive Care Unit (ICU) admission or later during their ICU stay with arterial hypotension (Mean arterial pressure [MAP]<65mmHg or systolic arterial pressure [SAP]< 90 mmHg at least two times over a 15-minute interval), regardless of the method used to measure blood pressure (invasive or non invasive),
- Or patients already receiving continuous iv vasopressor therapy on ICU admission, regardless of the blood pressure level, will be considered as potential candidates for inclusion in the study, depending on his/her clinical evolution after 6 to 24 hours of care according to current guidelines for shock management.
- In case arterial hypotension is present and/or the patient is already receiving continuous iv vasopressor at ICU admission, the date and time of admission will be considered as the time of shock onset (H0).
- In case arterial hypotension occurs after ICU admission, the date and time of the first episode of hypotension will be considered as the time of shock onset (H0).
Inclusion Criteria:
- Patients will be eligible for inclusion if 6 hours after H0 (and before H24) all the following conditions are present:
- Informed consent obtained (or emergency inclusion possible when legal representatives and patient's family are not present, as allowed by the Ethic Committee and by the French Law)
- Persistence of arterial hypotension (as defined above) or continuous iv infusion of norepinephrine
- Patient under invasive mechanical ventilation
- At least one of the following conditions is present
- Alteration of consciousness
- Mottling skin
- Cyanosis of the extremities despite SaO2>90%
- Oliguria defined as urine output below 0.5ml/kg of actual body weight over at least 1 hour
- Arterial lactate > 2 mmol/L
- ScvO2 < 70%
- Central venous (internal jugular or subclavian) or femoral venous catheter in place
- Arterial catheter in place
Exclusion Criteria:
- Shock began more than 24 hours ago
- Age < 18 yrs.
- Pregnancy
- Uncontrolled haemorrhage
- Intra-aortic balloon counterpulsation in place
- Patient under veno-arterial extracorporeal membrane oxygenation (V-A ECMO)
- Cardiogenic pulmonary oedema during the past 24 hours
- Patient equipped with a cardiac output monitoring device
- Brain death
- Moribund patient
- Traction of a lower limb
- Amputated lower limb above the ankle level
- Documented intra-abdominal hypertension
13. Cardiac arrest motivating ICU admission or cardiac arrest since admission 14. Patient without social security number 15. Consent refusal
Sites / Locations
- Centre Hospitalier Régional d'Orléans, FranceRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Other
"PLR-induced SV changes" based strategy
"PLR-induced PP changes" based strategy
Usual Care
During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Stroke Volume (SV) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if SV changes ≥10%, or no administration otherwise. Measurement of beat-to-beat stroke volume by intraarterial pulse contour analysis using the PiCCO system (Pulsion, Germany) will be used to assess stroke volume changes. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Pulse Pressure (PP) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if PP changes ≥10%, or no administration otherwise. We will perform measurement of intraarterial blood pressure using vascular pressure transducers (Edwards Life Science, USA). Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the fluid bolus will be administered without measurement of any predictive index of fluid responsiveness. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.